More meaningful endpoints for clinical trials, better communication for necessary study designs and an improved approval process have led to more efficient FDA approvals for ophthalmologic drugs and devices in 2018.
While there have been few drastic changes in the FDA’s approval process in the last 30 years, communication between the FDA and medical industry has improved, Wiley Chambers, MD, deputy director of the Division of Transplant and Ophthalmology Products at the FDA, said.
“There has been a strong belief, during the entire time I’ve been here, that there should (Read more...)
Uncategorized